IBX 5.88% 3.2¢ imagion biosystems limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-39

  1. 782 Posts.
    lightbulb Created with Sketch. 158
    I liked this part: "We need revenue pure and simple".

    Indeed we could look at it as a marketing exercise, sequencing activities and attempting to generate revenue at the earliest opportunity.

    In which case the simple, discrete Gadolinium replacement would have been a priority as 'the' trial ground on YoY, leading to revenue and SP appreciation while waiting for the big developments. And resulting in getting the name out there, to pave the way for bigger things.

    Instead, it seems like the long pole in the tent was the main focus, and quicker wins were missed. Which has seen us go from ~20c to the current SP, as there was nothing generating revenue, and only a cloud of vagueness upon which to speculate.

    It is obviously a complex space. But doing an environment analysis, identifying opportunities and risks, should be part of Management101.

    GLTAH.
 
watchlist Created with Sketch. Add IBX (ASX) to my watchlist
(20min delay)
Last
3.2¢
Change
-0.002(5.88%)
Mkt cap ! $1.140M
Open High Low Value Volume
3.2¢ 3.2¢ 3.1¢ $1.241K 38.80K

Buyers (Bids)

No. Vol. Price($)
2 48498 3.1¢
 

Sellers (Offers)

Price($) Vol. No.
3.2¢ 3776 1
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
IBX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.